Astellas

On target clinical trial success bullseye score
Pharma

Keytruda, Padcev cut risk of death by 50% in MIBC patient subset

The perioperative PD-1/ADC combo also significantly improved event-free survival by 60% versus surgery alone.
Angus Liuu Oct 18, 2025 10:30am
newspaper

China deals, Daiichi-Merck ADC, Sun Pharma—Fierce Pharma Asia

Sep 11, 2025 8:50pm
newspaper

Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia

Aug 15, 2025 8:31am
Graphic of a dart right on a bullseye sun breaking through the clouds in the background

Padcev-Keytruda combo delivers bladder cancer 'breakthrough'

Aug 12, 2025 11:16am
delay

FDA delays decision on Bayer's menopause drug elinzanetant

Jul 28, 2025 10:33am
newspaper

China biotech deals, Takeda, LaNova—Fierce Pharma Asia

Jul 18, 2025 9:04am